Over the past 2 years, commercially insured patients enrolled in plans that had value-based contracts for certain high-cost drugs had lower copays for their medications than did patients enrolled in plans without such contracts. That finding comes from “Delivering Results for Patients: The Value of Value-Based Contracts,” a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Over the past 2 years, commercially insured patients enrolled in plans that had value-based contracts for certain high-cost drugs had lower copays for their medications than did patients enrolled in plans without such contracts. That finding comes from “Delivering Results for Patients: The Value of Value-Based Contracts,” a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA’s report identifies the following types of value-based contracts:
According to PhRMA, value-based contracting has the potential benefit of allowing for broader access to innovative medicines by reducing the payers’ risk of suboptimal outcomes and encouraging the appropriate use of medicines. These agreements may also help to reduce medicine costs, says PhRMA, if manufacturers pay higher rebates for patients who do not meet their outcome targets. Patients could realize a savings if rebates are passed on to them.
As a result of these potential benefits, many health plans are warming to the idea of value-based arrangements, especially in the form of outcomes-based contracts, according the report. PhRMA says that, according to a 2017 Avalere Health report on payer perspectives on outcomes contracting, approximately 70% of commercial plans have a favorable view of this contract type, approximately 25% have implemented at least 1 such contract, and 30% report that they are negotiating a contract or contracts.
Among plans that have at least 1 outcomes-based contract, 55% report that they have entered into a contract that focuses on endocrine disorders—including diabetes—and another 33% are considering doing so. “If new value-based contracts are able to improve use of medicines for diabetes and reduce the burden of this disease in the United States by as little as [5%], these contracts could save nearly $9 billion annually in direct medical costs by preventing 365,000 emergency department visits, 390,000 hospital outpatient visits and 1.3 million hospital inpatient days,” according to the report.
Patients, too, could see a positive financial impact from such contracts. PhRMA says that it has worked with Avalere Health to analyze formulary coverage for existing outcomes-based contracts, including those for drugs that treat diabetes, high cholesterol, and HIV. Copays for patients enrolled in silver-level exchange plans with outcomes-based contracts were an average of 28% lower for these drugs than they were for patients enrolled in market average silver-level exchange plans.
However, barriers to value-based contracts—including concerns about how such arrangements might affect price reporting, issues with potentially implicating the federal anti-kickback statue, and uncertainty about the FDA’s rules regarding manufacturers’ communications with plans—make it difficult to accurately judge the potential that these contracts could have, says PhRMA.
“Small policy changes to modernize outdated regulations have the potential to lead to tremendous benefits for patients and the health care system,” the report concludes.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.